العلاج المساعد بعد استئصال الورم الميلانيني الجلدي في المرحلة IIB أو IIC

References

DOI: 10.1200/JCO.23.01136

• Adjuvant pembrolizumab or nivolumab should be offered to patients with resected stage IIB or IIC melanoma.
• Pembrolizumab 200 mg iv once every 3 weeks for 52 weeks (EORTC 13259)
• Nivolumab 240 mg iv once every 2 weeks or once 480 mg iv once every 4 weeks for 52 weeks (CheckMate 23810 and US FDA label)